- Home
- CHWY vs ABVX Comparison
CHWY vs ABVX Comparison
Compare CHWY & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHWY | ABVX |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | United States | France |
| Employees | N/A | 67 |
| Industry | Catalog/Specialty Distribution | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0B | 9.7B |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | CHWY | ABVX |
|---|---|---|
| Price | $24.65 | $117.75 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 24 | 13 |
| Target Price | $43.52 | ★ $131.31 |
| AVG Volume (30 Days) | ★ 6.6M | 739.1K |
| Earning Date | 06-10-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $12,601,500,000.00 | N/A |
| Revenue This Year | $10.70 | $52.14 |
| Revenue Next Year | $7.84 | $4,132.27 |
| P/E Ratio | $49.04 | ★ N/A |
| Revenue Growth | ★ 6.24 | N/A |
| 52 Week Low | $22.74 | $5.59 |
| 52 Week High | $48.62 | $148.83 |
Technical Indicators
Market Signals| Indicator | CHWY | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 40.90 | 50.63 |
| Support Level | $22.90 | $107.55 |
| Resistance Level | $27.77 | $129.84 |
| Average True Range (ATR) | 1.18 | 5.01 |
| MACD | -0.22 | -0.03 |
| Stochastic Oscillator | 0.43 | 50.59 |
Price Performance
Historical ComparisonAbout CHWY Chewy Inc.
Chewy is the largest e-commerce petcare retailer in the US, generating $11.9 billion in fiscal 2024 sales across pet food, treats, hard goods, and pharmacy categories. The firm was founded in 2011, acquired by PetSmart in 2017, and tapped public markets as a stand-alone company in 2019 after spending time developing under the aegis of the pet superstore chain. The firm generates sales from pet food, treats, over-the-counter medications, medical prescription fulfillment, and hard goods like crates, leashes, and bowls.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.